drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Bispecific T-cell engager (BiTE) antibody that links CD3 on T cells to CD19 on B-lineage ALL blasts, redirecting T-cell cytotoxicity and inducing cytokine release; given by continuous infusion.
nci_thesaurus_concept_id
C62528
nci_thesaurus_preferred_term
Blinatumomab
nci_thesaurus_definition
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.
drug_mesh_term
Blinatumomab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Single-chain bispecific antibody (BiTE) that binds CD3 on T cells and CD19 on B-lineage cells, physically bringing them together to form an immunologic synapse and redirect T-cell cytotoxicity (perforin/granzyme) against CD19+ blasts, with associated cytokine release; active independent of MHC.
drug_name
Blinatumomab
nct_id_drug_ref
NCT05519579